— Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan —
SOUTH SAN FRANCISCO, CA, USA I June 22, 2017 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL). This new treatment includes the same monoclonal antibody as intravenous Rituxan® (rituximab) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.
“With today’s approval of RITUXAN HYCELA, people with three of the most common blood cancers now have a new treatment option which provides efficacy comparable with intravenous Rituxan and can be delivered under the skin in minutes instead of hours through IV infusion,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “People who benefit from Rituxan may receive years of repeated treatments for their blood cancer, so an option that reduces the administration time can be important.”
The FDA approval is based on results from clinical studies, which demonstrated that subcutaneous administration of RITUXAN HYCELA resulted in non-inferior levels of rituximab in the blood (pharmacokinetics) and comparable clinical efficacy outcomes compared to intravenous Rituxan. One of the studies showed the majority (77 percent) of patients preferred RITUXAN HYCELA over intravenous Rituxan, with the most common reason being that administration required less time in the clinic. People can only receive RITUXAN HYCELA after at least one full dose of intravenous Rituxan.
With the exception of local skin (cutaneous) reactions, the incidence and profile of adverse reactions for RITUXAN HYCELA were comparable with those for intravenous Rituxan. The most common (≥20 percent) adverse reactions observed with RITUXAN HYCELA in people with follicular lymphoma were infections, low white blood cell count (neutropenia), nausea, constipation, cough and fatigue. The most common adverse reactions in people with DLBCL were infections, neutropenia, hair loss (alopecia), nausea and low red blood cell count (anemia). The most common adverse reactions in people with CLL were infections, neutropenia, nausea, low platelet count (thrombocytopenia), fever (pyrexia), vomiting and reddening of the skin (erythema) at the injection site.
RITUXAN HYCELA will be available to people in the United States within one to two weeks, and intravenous Rituxan will continue to be available. For those who qualify, Genentech plans to offer patient assistance programs for people taking RITUXAN HYCELA through Genentech Access Solutions. Doctors can contact Genentech Access Solutions at (888) 249-4918. More information is also available at http://www.Genentech-Access.com.
About the RITUXAN HYCELA Clinical Development Program
The approval of RITUXAN HYCELA is based on results from clinical studies that together represented nearly 2,000 people. The studies were the following:
- SABRINA (NCT01200758): Phase III combination with chemotherapy and maintenance study in previously untreated follicular lymphoma
- SAWYER (NCT01292603): Phase Ib study in previously untreated chronic lymphocytic leukemia (CLL)
- MabEase (NCT01649856): Phase III study in previously untreated diffuse large B-cell lymphoma (DLBCL)
- PrefMab (NCT01724021): Phase III patient preference study in previously untreated follicular lymphoma and DLBCL
About Follicular Lymphoma
Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), accounting for about one in five cases of NHL. It is considered incurable and relapse is common. In the United States, it is estimated that more than 14,000 new cases of follicular lymphoma will be diagnosed in 2017.
About Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL is the most common form of non-Hodgkin’s lymphoma (NHL), accounting for about one in three cases of NHL. DLBCL is an aggressive (fast-growing) type of NHL. As many as 40 percent of patients will relapse, at which point their prognosis is poor. In the United States, it is estimated that more than 24,000 new cases of DLBCL will be diagnosed in 2017.
About Chronic Lymphocytic Leukemia (CLL)
CLL is the most common type of adult leukemia, and in 2017, it is estimated there will be more than 20,000 new cases of CLL diagnosed in the United States. Although signs of CLL may disappear for a period of time after initial treatment, the disease is considered incurable and many people will require additional treatment due to the return of cancerous cells.
About Genentech Access Solutions
Access Solutions is part of Genentech’s commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process, and to providing assistance to eligible patients in the United States who are uninsured or cannot afford the out-of-pocket costs for their medicine. To date, the team has helped more than 1.5 million patients access the medicines they need. Please contact Access Solutions (866) 4ACCESS/(866) 422-2377 or visit http://www.Genentech-Access.com for more information.
About RITUXAN HYCELA
RITUXAN HYCELA is a combination of rituximab and Halozyme Therapeutics’ proprietary hyaluronidase human. Rituximab is the same monoclonal antibody in intravenous Rituxan and is designed to attach to CD20, a protein found on certain types of B-cells. It is thought to work by attacking targeted cells together with the body’s immune system. Halozyme’s hyaluronidase human is a well-established enzyme that facilitates the delivery of a large volume of medicine under the skin.
RITUXAN HYCELA can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan. Patients should be observed for at least 15 minutes following RITUXAN HYCELA. All patients must first receive at least one full dose of Rituxan by intravenous infusion without severe adverse reactions before they can receive RITUXAN HYCELA due to the higher risk of certain severe adverse reactions during the first infusion.
Rituxan was discovered by Biogen and is part of a collaboration between Genentech and Biogen in the United States.
RITUXAN HYCELA Indications
RITUXAN HYCELA™ (rituximab/hyaluronidase human) is a prescription medicine used to treat adults with:
- Follicular Lymphoma (FL) as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
- Follicular Lymphoma as an initial treatment with chemotherapy and, in patients whose initial treatment was successful, as a single-agent follow-up therapy
- Follicular Lymphoma as a single-agent follow-up therapy for patients who did not progress on initial treatment with CVP chemotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL) as an initial treatment in combination with CHOP or other anthracycline-based chemotherapy regimens
- Chronic Lymphocytic Leukemia (CLL) in combination with FC chemotherapy as an initial treatment or as a treatment after disease has recurred
About Genentech In Hematology
For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. In addition to approved medicines, Genentech’s pipeline of investigational hematology medicines includes an anti-CD79b antibody drug conjugate (polatuzumab vedotin/RG7596) and a small molecule antagonist of MDM2 (idasanutlin/RG7388). Genentech’s dedication to developing novel medicines for blood diseases expands beyond oncology, with the development of the investigational hemophilia A treatment emicizumab. For more information visit http://www.gene.com/hematology .
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
SOURCE: Genentech
Post Views: 308
— Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan —
SOUTH SAN FRANCISCO, CA, USA I June 22, 2017 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL). This new treatment includes the same monoclonal antibody as intravenous Rituxan® (rituximab) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.
“With today’s approval of RITUXAN HYCELA, people with three of the most common blood cancers now have a new treatment option which provides efficacy comparable with intravenous Rituxan and can be delivered under the skin in minutes instead of hours through IV infusion,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “People who benefit from Rituxan may receive years of repeated treatments for their blood cancer, so an option that reduces the administration time can be important.”
The FDA approval is based on results from clinical studies, which demonstrated that subcutaneous administration of RITUXAN HYCELA resulted in non-inferior levels of rituximab in the blood (pharmacokinetics) and comparable clinical efficacy outcomes compared to intravenous Rituxan. One of the studies showed the majority (77 percent) of patients preferred RITUXAN HYCELA over intravenous Rituxan, with the most common reason being that administration required less time in the clinic. People can only receive RITUXAN HYCELA after at least one full dose of intravenous Rituxan.
With the exception of local skin (cutaneous) reactions, the incidence and profile of adverse reactions for RITUXAN HYCELA were comparable with those for intravenous Rituxan. The most common (≥20 percent) adverse reactions observed with RITUXAN HYCELA in people with follicular lymphoma were infections, low white blood cell count (neutropenia), nausea, constipation, cough and fatigue. The most common adverse reactions in people with DLBCL were infections, neutropenia, hair loss (alopecia), nausea and low red blood cell count (anemia). The most common adverse reactions in people with CLL were infections, neutropenia, nausea, low platelet count (thrombocytopenia), fever (pyrexia), vomiting and reddening of the skin (erythema) at the injection site.
RITUXAN HYCELA will be available to people in the United States within one to two weeks, and intravenous Rituxan will continue to be available. For those who qualify, Genentech plans to offer patient assistance programs for people taking RITUXAN HYCELA through Genentech Access Solutions. Doctors can contact Genentech Access Solutions at (888) 249-4918. More information is also available at http://www.Genentech-Access.com.
About the RITUXAN HYCELA Clinical Development Program
The approval of RITUXAN HYCELA is based on results from clinical studies that together represented nearly 2,000 people. The studies were the following:
- SABRINA (NCT01200758): Phase III combination with chemotherapy and maintenance study in previously untreated follicular lymphoma
- SAWYER (NCT01292603): Phase Ib study in previously untreated chronic lymphocytic leukemia (CLL)
- MabEase (NCT01649856): Phase III study in previously untreated diffuse large B-cell lymphoma (DLBCL)
- PrefMab (NCT01724021): Phase III patient preference study in previously untreated follicular lymphoma and DLBCL
About Follicular Lymphoma
Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), accounting for about one in five cases of NHL. It is considered incurable and relapse is common. In the United States, it is estimated that more than 14,000 new cases of follicular lymphoma will be diagnosed in 2017.
About Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL is the most common form of non-Hodgkin’s lymphoma (NHL), accounting for about one in three cases of NHL. DLBCL is an aggressive (fast-growing) type of NHL. As many as 40 percent of patients will relapse, at which point their prognosis is poor. In the United States, it is estimated that more than 24,000 new cases of DLBCL will be diagnosed in 2017.
About Chronic Lymphocytic Leukemia (CLL)
CLL is the most common type of adult leukemia, and in 2017, it is estimated there will be more than 20,000 new cases of CLL diagnosed in the United States. Although signs of CLL may disappear for a period of time after initial treatment, the disease is considered incurable and many people will require additional treatment due to the return of cancerous cells.
About Genentech Access Solutions
Access Solutions is part of Genentech’s commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process, and to providing assistance to eligible patients in the United States who are uninsured or cannot afford the out-of-pocket costs for their medicine. To date, the team has helped more than 1.5 million patients access the medicines they need. Please contact Access Solutions (866) 4ACCESS/(866) 422-2377 or visit http://www.Genentech-Access.com for more information.
About RITUXAN HYCELA
RITUXAN HYCELA is a combination of rituximab and Halozyme Therapeutics’ proprietary hyaluronidase human. Rituximab is the same monoclonal antibody in intravenous Rituxan and is designed to attach to CD20, a protein found on certain types of B-cells. It is thought to work by attacking targeted cells together with the body’s immune system. Halozyme’s hyaluronidase human is a well-established enzyme that facilitates the delivery of a large volume of medicine under the skin.
RITUXAN HYCELA can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan. Patients should be observed for at least 15 minutes following RITUXAN HYCELA. All patients must first receive at least one full dose of Rituxan by intravenous infusion without severe adverse reactions before they can receive RITUXAN HYCELA due to the higher risk of certain severe adverse reactions during the first infusion.
Rituxan was discovered by Biogen and is part of a collaboration between Genentech and Biogen in the United States.
RITUXAN HYCELA Indications
RITUXAN HYCELA™ (rituximab/hyaluronidase human) is a prescription medicine used to treat adults with:
- Follicular Lymphoma (FL) as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
- Follicular Lymphoma as an initial treatment with chemotherapy and, in patients whose initial treatment was successful, as a single-agent follow-up therapy
- Follicular Lymphoma as a single-agent follow-up therapy for patients who did not progress on initial treatment with CVP chemotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL) as an initial treatment in combination with CHOP or other anthracycline-based chemotherapy regimens
- Chronic Lymphocytic Leukemia (CLL) in combination with FC chemotherapy as an initial treatment or as a treatment after disease has recurred
About Genentech In Hematology
For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. In addition to approved medicines, Genentech’s pipeline of investigational hematology medicines includes an anti-CD79b antibody drug conjugate (polatuzumab vedotin/RG7596) and a small molecule antagonist of MDM2 (idasanutlin/RG7388). Genentech’s dedication to developing novel medicines for blood diseases expands beyond oncology, with the development of the investigational hemophilia A treatment emicizumab. For more information visit http://www.gene.com/hematology .
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
SOURCE: Genentech
Post Views: 308
